Diagnostic Accuracy in Sepsis Act of 2025
- Bill Number
- H.R. 5275
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-09-10: Referred to the House Committee on Ways and Means.
- Last Updated
- 2026-06-24T08:08:34Z
AI-Generated Summary
Purpose
The Diagnostic Accuracy in Sepsis Act of 2025 aims to enhance the accuracy of sepsis diagnoses by classifying blood culture contamination as a hospital-acquired condition (HAC) under Medicare. This encourages hospitals to reduce contamination rates in blood tests, which can lead to misdiagnoses of infections like sepsis, a serious bloodstream condition.
Key Provisions
- Addition to HAC List: Amends Section 1886(p) of the Social Security Act to include "blood culture contamination" as an HAC for hospital discharges occurring in fiscal year 2026 or later.
- Definition Update: Expands the HAC definition to explicitly cover blood culture contamination, alongside existing conditions like those from surgical-site infections or certain vascular catheter infections.
- Performance Measure: Requires the Secretary of Health and Human Services (who oversees Medicare) to establish a measure for blood culture contamination in hospitals. This measure sets a target where the contamination rate should not exceed 1% to avoid penalties.
- Application Scope: Applies only to "subsection (d)" hospitals, which are general acute care hospitals paid under Medicare's inpatient prospective payment system.
Significant Changes to Existing Law
- Previously, HACs under Medicare (introduced via the 2008 Medicare Improvements for Patients and Providers Act) included conditions like pressure ulcers or certain infections acquired during hospitalization, which trigger payment reductions if not present on admission. This bill adds blood culture contamination—a lab error where a blood sample is contaminated by skin bacteria during collection or processing—as a new HAC category.
- Introduces a specific 1% threshold for contamination rates, which is a new quantifiable standard not previously defined for this issue in Medicare rules.
- Shifts paragraph numbering in the law for clarity, redesignating existing paragraph (7) as (8) to insert the new blood culture provision.
Potential Impacts
- On Government Agencies: The Centers for Medicare & Medicaid Services (CMS) will need to develop and implement the new contamination measure, potentially increasing administrative workload for monitoring and enforcement starting in FY 2026.
- On Citizens (Patients): Could improve patient safety by reducing false positives in sepsis testing, leading to more accurate diagnoses, fewer unnecessary antibiotics, and better treatment outcomes. Medicare beneficiaries in hospitals may indirectly benefit from higher-quality lab practices.
- On Hospitals: May result in financial penalties (up to 1% reduction in Medicare payments) for hospitals exceeding the 1% contamination rate, incentivizing investments in staff training, better equipment, or protocols for blood draws.
- On International Relations: No direct impact, as this is a domestic Medicare policy focused on U.S. hospitals.
Main Stakeholders Affected
- Hospitals and Healthcare Providers: Primarily subsection (d) hospitals and lab staff involved in blood cultures, who must meet the new standards to avoid payment cuts.
- Medicare Beneficiaries: Elderly and disabled patients relying on Medicare for hospital care, who stand to gain from improved diagnostic accuracy.
- Federal Government (CMS and HHS): Responsible for creating the measure, tracking compliance, and adjusting payments.
- Medical Community: Organizations like the American Hospital Association or sepsis advocacy groups, which may influence or respond to implementation.
Notable Legal, Constitutional, or Political Implications
- Legal: Strengthens Medicare's HAC Reduction Program by broadening its scope to lab-related errors, potentially setting a precedent for including diagnostic inaccuracies in payment penalties. Hospitals could challenge the 1% threshold in court if deemed arbitrary, though it aligns with existing CMS authority to define measures.
- Constitutional: No apparent issues, as it operates within Congress's spending power under Medicare and does not infringe on individual rights.
- Political: Bipartisan introduction (by Rep. Kelly (R-PA) and Rep. Craig (D-MN)) suggests broad support for patient safety initiatives. Could spark debates on hospital funding burdens versus quality improvements, especially amid ongoing concerns about sepsis mortality rates in the U.S. (affecting over 1.7 million people annually).
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (6)
Rep. Craig, Angie [D-MN-2], Rep. Gottheimer, Josh [D-NJ-5], Rep. Vindman, Eugene Simon [D-VA-7], Rep. Smith, Adrian [R-NE-3], Rep. Hern, Kevin [R-OK-1], Rep. Miller, Carol D. [R-WV-1]
Recent Actions
- 2025-09-10: Referred to the House Committee on Ways and Means.
- 2025-09-10: Introduced in House
- 2025-09-10: Introduced in House
Bill Versions
- Diagnostic Accuracy in Sepsis Act of 2025 — issued 2025-09-10 — PDF (3 pages)